- Conditions
- Hypogonadism
- Interventions
- Nasobol®, Androderm® (Positive Control)
- Drug
- Lead sponsor
- Acerus Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 68
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypothalamic Amenorrhea, Functional, Hypothalamic Amenorrhea, Functional Hypogonadotropic Hypogonadism
- Interventions
- Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24), REVEAL Questionnaire
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Endocrine Disease, Infertility, Hypogonadism, Amenorrhea, Adolescents
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 14 Years to 100 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Research Triangle Park, North Carolina
- Conditions
- Hypogonadotropic Hypogonadism, Kallmann Syndrome, Puberty, Delayed, Puberty, Precocious, GnRH Deficiency
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 4,042 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypogonadism
- Interventions
- testosterone, placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 30 Years to 65 Years · Male only
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction
- Interventions
- fispemifene, Placebo
- Drug · Other
- Lead sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • San Diego, California • Bradenton, Florida + 12 more
- Conditions
- Healthy Volunteers
- Interventions
- Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- intranasal insulin, placebo (intranasal saline)
- Drug
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Odessa, Texas
- Conditions
- Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
- Interventions
- kisspeptin 112-121, GnRH
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal 25 mg
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hypogonadism
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 200 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
- Interventions
- Testosterone Gel (1%)
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 13 Years to 17 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more
- Conditions
- Type 2 Diabetes Mellitus, Secondary Hypogonadism
- Interventions
- Placebo, Androxal
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 20 Years to 80 Years · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 18
- States / cities
- Garden Grove, California • Sacramento, California • Torrance, California + 11 more
- Conditions
- Primary Amenorrhea With Hypogonadotropic Hypogonadism
- Interventions
- Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
- Conditions
- Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
- Interventions
- androgel, placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 31 Years to 60 Years · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- 5-day controlled metabolic dietary intake
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hypogonadism
- Interventions
- Testosterone gel 1.62%
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Miami Gardens, Florida
- Conditions
- Hypogonadism
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1993 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- BGS649, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
- Conditions
- Effect of Treatment on Bone Mineral Density
- Interventions
- enclomiphene citrate, Placebo
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 17
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 14 more
- Conditions
- Hypogonadotropic Hypogonadism, Type 2 Diabetes
- Interventions
- testosterone, clomiphene, placebo
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
- Interventions
- GnRH, Pump
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal, AndroGel, Placebo
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- kisspeptin 112-121, GnRH
- Drug
- Lead sponsor
- Stephanie B. Seminara, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts